- Home
- GES vs RGNX Comparison
GES vs RGNX Comparison
Compare GES & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GES | RGNX |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.4M | 732.0M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GES | RGNX |
|---|---|---|
| Price | $16.78 | $13.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $19.88 | ★ $30.78 |
| AVG Volume (30 Days) | 367.0K | ★ 662.8K |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,144,417,000.00 | $161,318,000.00 |
| Revenue This Year | $8.97 | $132.80 |
| Revenue Next Year | $4.07 | $45.32 |
| P/E Ratio | $15.63 | ★ N/A |
| Revenue Growth | 6.44 | ★ 91.30 |
| 52 Week Low | $8.48 | $5.04 |
| 52 Week High | $17.15 | $15.41 |
Technical Indicators
Market Signals| Indicator | GES | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 49.74 |
| Support Level | $16.73 | $13.66 |
| Resistance Level | $16.85 | $15.41 |
| Average True Range (ATR) | 0.04 | 0.97 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 41.67 | 29.04 |
Price Performance
Historical ComparisonAbout GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.